Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26015271 | 0.86 | SIGMAR1 (0.45) | SIGMAR1PRCP | |
| SCHEMBL26015090 | 0.85 | SIGMAR1 (0.44) | SIGMAR1PRCP | |
| SCHEMBL26014965 | 0.85 | SIGMAR1 (0.41) | SIGMAR1PRCPGLP1R | |
| SCHEMBL26004355 | 0.83 | SIGMAR1 (0.44) | SIGMAR1PRCP | |
| SCHEMBL26004734 | 0.83 | SIGMAR1 (0.46) | SIGMAR1PRCP | |
| SCHEMBL26014962 | 0.83 | SIGMAR1 (0.45) | SIGMAR1DRD2KCNH2ENPP2PRCP | |
| SCHEMBL26015093 | 0.83 | SIGMAR1 (0.48) | SIGMAR1DRD2PRCP | |
| SCHEMBL26004752 | 0.82 | SIGMAR1 (0.45) | SIGMAR1PRCP | |
| SCHEMBL26004354 | 0.82 | SIGMAR1 (0.49) | SIGMAR1PRCP | |
| SCHEMBL26015269 | 0.81 | MEN1 (0.48) | SIGMAR1PRCPLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |